GENE ONLINE|News &
CYP2C19 Genetic Polymorphisms Influence Diazepam Effectiveness in Pediatric Status Epilepticus Treatment
Researchers Seker Gezici, C. Turan, and D. Ayyildiz Emecen recently completed a prospective cohort study examining how CYP2C19 genetic polymorphisms influence the effectiveness of diazepam in treating pediatric convulsive status epilepticus (CSE). The study, which will appear in the journal *BMC Pharmacology and Toxicology*, identifies a correlation between specific genetic variations and the clinical response to diazepam administration in children experiencing prolonged seizures.
The research team analyzed how different genetic profiles affect the metabolism and therapeutic efficacy of the drug within the pediatric population. By tracking patient outcomes in relation to their CYP2C19 genotypes, the investigators documented how these biological differences alter the speed and success rate of seizure cessation. These findings provide data on the role of pharmacogenetics in emergency neurological care, specifically regarding the standard treatment protocols for pediatric patients suffering from status epilepticus.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: June 6, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
PYGO2 Overexpression Linked to Increased Plasma Cell Proliferation in Multiple Myeloma Patients with 1q21 Amplification
2026-07-10
Sean Kaufman Faces Senate Scrutiny Over Past Vaccine Safety Comments Ahead of Confirmation Hearing
2026-07-10
IBEC and European Researchers Receive Novo Nordisk Foundation Grant to Study Physics of Living Matter
2026-07-10
Manufacturers Integrate Commercial, Government, and Cash-Pay Strategies to Optimize Product Life Cycle Value
2026-07-10
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
